Intra-Cellular Therapies, Inc.

NASDAQ:ITCI

73.54 (USD) • At close September 6, 2024
Bedrijfsnaam Intra-Cellular Therapies, Inc.
Symbool ITCI
Munteenheid USD
Prijs 73.54
Beurswaarde 7,770,751,180
Dividendpercentage 0%
52-weken bereik 45.5 - 84.89
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. Sharon Mates Ph.D.
Website https://www.intracellulartherapies.com

An error occurred while fetching data.

Over Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which

Vergelijkbare Aandelen

Azenta, Inc. logo

Azenta, Inc.

AZTA

47.81 USD

Ionis Pharmaceuticals, Inc. logo

Ionis Pharmaceuticals, Inc.

IONS

46.89 USD

10x Genomics, Inc. logo

10x Genomics, Inc.

TXG

21.54 USD

Option Care Health, Inc. logo

Option Care Health, Inc.

OPCH

32.1 USD

HealthEquity, Inc. logo

HealthEquity, Inc.

HQY

76.24 USD

Integra LifeSciences Holdings Corporation logo

Integra LifeSciences Holdings Corporation

IART

18.5 USD

Exelixis, Inc. logo

Exelixis, Inc.

EXEL

25.15 USD

Omnicell, Inc. logo

Omnicell, Inc.

OMCL

45.29 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)